Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy.

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Multiple myeloma (MM) is a plasma cell malignancy characterized by genomic instability and DNA damage.
• The DNA damage response (DDR) pathway is crucial for coordinating DNA repair and cell-cycle progression following genotoxic stress.
• Epigenetic modifications, including acetylation, play a significant role in regulating DDR proteins and overall carcinogenesis.

Purpose of the Study:

• To summarize the role of histone deacetylase inhibitors (HDACi) in the DNA damage response (DDR) in multiple myeloma (MM).
• To elucidate the interference of HDACi with specific DNA repair mechanisms.
• To discuss the therapeutic implications of HDACi for MM treatment.

Main Methods:

• Review of existing pre-clinical and clinical data on HDAC inhibitors in MM.
• Analysis of the impact of HDACi on DNA damage response pathways.
• Examination of the interplay between HDAC inhibition and DNA repair mechanisms.

Main Results:

• HDAC inhibitors exhibit significant anti-MM activities in pre-clinical and clinical studies.
• HDACi modulate posttranslational modifications, affecting key DDR and checkpoint proteins.
• The reversibility of epigenetic changes makes epigenetic therapies a potent strategy for MM.

Conclusions:

• HDAC inhibitors are a promising therapeutic strategy for multiple myeloma due to their ability to modulate the DDR.
• Targeting epigenetic modifications offers a potent approach to combat MM, a disease driven by genomic instability.
• Further research into HDACi mechanisms and their interference with DNA repair pathways is crucial for optimizing MM treatment.